USPTO serial 79370605
Reviewed by CopyMark Law Group
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd.
CN
Other trademarks owned by Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd.
Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd.
CN
Other trademarks owned by Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd.
Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd.
CN
Other trademarks owned by Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd.
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Medicines for the treatment and control of inflammation and immune system related diseases; pharmaceutical preparations for inflammation and immune system related diseases; chemical preparations for pharmaceutical or medical purposes, namely, for inflammation and immune system related diseases; biological preparations for the treatment and control of inflammation and immune system related diseases; allergy relief medication; allergy medication | ACTIVE | — |
| 042 | Biotechnology research; biomedical research services; pharmaceutical research services; scientific research and development; research and development of new products for others; scientific laboratory services; quality control for others; quality evaluation services for the medical and anesthesia industries; scientific research and development in the field of immunity and antibody screening; research and development services in the field of antibodies | ACTIVE | — |
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 2, 2024 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jul 2, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Apr 16, 2024 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Apr 16, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Mar 27, 2024 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Mar 27, 2024 | NPUB | NOTICE OF PUBLICATION | — |
| Mar 27, 2024 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Mar 11, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Feb 14, 2024 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jan 19, 2024 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jan 19, 2024 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Dec 2, 2023 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Dec 1, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 1, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 6, 2023 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jun 1, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jun 1, 2023 | LIMI | LIMITATION FROM ORIGINAL APPLICATION ENTERED | — |
| May 25, 2023 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |